Provenance du réseau au premier degré de William Fricker
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Subsidiary | Biotechnology | 13 | |
| Public Company | Pharmaceuticals: Major | 8 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à William Fricker via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
NeuroRx, Inc.
 NeuroRx, Inc. BiotechnologyHealth Technology NeuroRx, Inc. operates as a clinical stage, small molecule pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders. The company was founded by Jonathan C. Javitt and Daniel C. Javitt in 2015 and is headquartered in Wilmington, DE. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal General Counsel | |
| INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO General Counsel Chief Operating Officer | |
| Yale University | College/University | Doctorate Degree Undergraduate Degree | |
| AADI BIOSCIENCE, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Masters Business Admin | |
| JOUNCE THERAPEUTICS, INC. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Mallinckrodt LLC
 Mallinckrodt LLC Pharmaceuticals: MajorHealth Technology Mallinckrodt LLC is proud to be one of the world's largest suppliers of both controlled substance pain medication and acetaminophen and to have over a century of leadership in helping to diagnose disease through imaging procedures. They are focused on innovative research and development programs, strong clinician relationships and a collaborative approach to new business opportunities. In short, they aim to lead a new generation of patient care by pursuing better, safer, more cost effective ways of diagnosing and treating disease to improve patient outcomes. | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Director/Board Member Sales & Marketing | |
| ADAPTIMMUNE THERAPEUTICS PLC | Biotechnology | Director of Finance/CFO Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Undergraduate Degree | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member Director/Board Member | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Pennsylvania | College/University | Graduate Degree Undergraduate Degree | |
| ALDER BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| CLOVIS ONCOLOGY, INC. | Pharmaceuticals: Major | Director/Board Member | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member | |
Amgen Europe BV
 Amgen Europe BV Medical DistributorsDistribution Services Part of Amgen, Inc., Amgen Europe BV wholesales pharmaceutical products. The company is based in Breda, Netherlands. | Medical Distributors | Corporate Officer/Principal | |
| Harvard Business School | College/University | Masters Business Admin | |
| ELIEM THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
| CHINOOK THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ADC THERAPEUTICS SA | Pharmaceuticals: Major | Director/Board Member | |
| CARDINAL HEALTH, INC. | Medical Distributors | Director/Board Member | |
| CELGENE | Biotechnology | Corporate Officer/Principal | |
| Ludwig-Maximilians-Universität München | College/University | Undergraduate Degree | |
GEMoaB Monoclonals GmbH
 GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Part of AvenCell Therapeutics, Inc., GEMoaB Monoclonals GmbH is a German company that manufactures biopharmaceutical products. The company is based in Dresden, Germany. The company was founded in 2014 by Gerhard Ehninger. GEMoaB Monoclonals was acquired by AvenCell Therapeutics, Inc. from Cellex Cell Professionals GmbH on March 30, 2022. | Pharmaceuticals: Major | Chief Executive Officer | |
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Biotechnology | Chief Executive Officer | |
| University of Virginia | College/University | Undergraduate Degree | |
| ACRIVON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| MIRATI THERAPEUTICS | Biotechnology | Chief Executive Officer | |
| ARRAY TECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Washington University School of Medicine | College/University | Doctorate Degree | |
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Packaged Software | Chairman | |
| PMV PHARMACEUTICALS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | Packaged Software | Director/Board Member | |
| POSEIDA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
| JUNO THERAPEUTICS INC | Biotechnology | Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| JAZZ PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Director/Board Member | |
| The Catholic University of America | College/University | Undergraduate Degree | |
| University of Pennsylvania Medical Center | College/University | Corporate Officer/Principal | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Jazz Pharmaceuticals, Inc.
 Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Pharmaceuticals: Major | Director/Board Member | |
| Queen's University | College/University | Masters Business Admin | |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistiques
Internationale
| Etats-Unis | 40 |
| Royaume-Uni | 4 |
| Allemagne | 3 |
| Pays-Bas | 2 |
| Suisse | 2 |
Sectorielle
| Health Technology | 32 |
| Consumer Services | 12 |
| Commercial Services | 3 |
| Distribution Services | 3 |
| Technology Services | 3 |
Opérationnelle
| Director/Board Member | 83 |
| Corporate Officer/Principal | 46 |
| Independent Dir/Board Member | 29 |
| Undergraduate Degree | 20 |
| Chief Executive Officer | 17 |
Relations les plus connectées
| Insiders | |
|---|---|
| Chaim Hurvitz | 26 |
| Barbara Duncan | 22 |
| Patrick J. Flynn | 17 |
| Robert Azelby | 15 |
| Dan Troy | 13 |
| Charles Baum | 12 |
| Robert Iannone | 12 |
| Loretta Itri | 12 |
| Sherry A. Glied | 10 |
| Bryan Ball | 9 |
| Alessandra Daigneault | 9 |
| Aaron Gorovitz | 8 |
| Michael R. Garone | 8 |
| Harout Semerjian | 8 |
| Herbert McMaster | 8 |
- Bourse
- Insiders
- William Fricker
- Connexions Sociétés
